Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiac gene therapy: therapeutic potential and current progress.

E Kizana1, I E Alexander

  • 1Department of Cardiology, Westmead Hospital, Westmead, New South Wales, Australia. eddyk@chw.edu.au

Current Gene Therapy
|October 8, 2003
PubMed
Summary

Gene therapy offers a promising new avenue for treating cardiovascular diseases, moving beyond inherited disorders to address complex acquired conditions. Research is building a strong foundation for exploring these innovative cardiac gene therapies in humans.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and echocardiographic characteristics of cardioembolic stroke.

European journal of neurology·2019
Same author

Delivering efficient liver-directed AAV-mediated gene therapy.

Gene therapy·2017
Same author

Synthetic certified DNA reference material for analysis of human erythropoietin transgene and transcript in gene doping and gene therapy.

Gene therapy·2016
Same author

Transient suppression of hepatocellular replication in the mouse liver following transduction with recombinant adeno-associated virus.

Gene therapy·2015
Same author

A novel intronic splice site deletion of the IL-2 receptor common gamma chain results in expression of a dysfunctional protein and T-cell-positive X-linked Severe combined immunodeficiency.

International journal of immunogenetics·2014
Same author

AAV-encoded OTC activity persisting to adulthood following delivery to newborn spf(ash) mice is insufficient to prevent shRNA-induced hyperammonaemia.

Gene therapy·2013

Area of Science:

  • Cardiovascular Medicine
  • Molecular Biology
  • Gene Therapy

Background:

  • Cardiovascular diseases (CVDs) are a leading cause of death globally, necessitating novel therapeutic strategies.
  • Current treatments for CVDs are advancing, but significant unmet needs persist.
  • Gene therapy presents a potential paradigm shift for managing cardiovascular conditions.

Purpose of the Study:

  • To review the potential of gene therapy for cardiovascular diseases.
  • To provide an overview of gene and vector delivery systems for cardiac applications.
  • To discuss the molecular targets and pathophysiology relevant to cardiac gene therapy.

Main Methods:

  • Review of in vitro and animal studies on gene therapy for cardiovascular diseases.
  • Analysis of gene and vector delivery systems suitable for cardiac conditions.

Related Experiment Videos

  • Examination of molecular targets and underlying pathophysiology of heart diseases.

    • Main Results:

    • Gene therapy shows potential for both inherited monogenic and acquired polygenic cardiovascular diseases.
    • Extensive preclinical data support the cautious evaluation of gene therapy in humans.
    • Specific gene and vector systems are being developed for targeted cardiac interventions.

    Conclusions:

    • Gene therapy holds significant promise for treating a range of cardiovascular diseases.
    • Advances in molecular pathology and gene transfer technology are enabling these novel approaches.
    • Further research and clinical evaluation are warranted to realize the full potential of cardiac gene therapy.